TA Associates adds to UK bioscience firm’s $62M coffers

By Mass High Tech Staff

TA Associates completes $60M e-Rewards funding [October 7, 2008]

Monotype Imaging makes $60M follow-on offering [June 13, 2008]

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

Spin Transfer whips up $36M in first round [February 13, 2012]

Global private equity firm TA Associates has invested about $62 million in British bioscience analytics and safety evaluation firm Quotient Bioscience Group Ltd., the companies reported. TA Associates has offices in Boston, London and Menlo Park, Calif.

As part of the deal, both TA Associates managing director Jonathan Goldstein and senior vice president Mark Carter will join Quotient Bioscience’s board of directors.

The funds will support Quotient Bioscience’s acquisition plans in Europe and North America, to add to the company’s four acquisitions made since January 2007 -- HFL Limited in January 2007; Alba Bioscience Limited in August 2007; GR Micro Limited in September 2007; and BioDynamics Research Limited in February 2008. Quotient Bioscience covers pharmaceutical and biotechnology drug development, blood typing reagents manufacturing and sales and drug surveillance in sports.

TA Associates, founded in 1968, operates a $12 billion capital management budget, with investments in more than 380 companies. The firm focuses on growth and buyouts in the technology, healthcare, business, consumer and financial services sectors.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.